Group 1: Company Overview - Xian New Tong Pharmaceutical Research Co., Ltd. focuses on drug development for major liver diseases, including hepatitis B and liver cancer, with 8 core products in its pipeline [1] - Renben Co., Ltd. is the largest comprehensive bearing manufacturing group in China, with over 50,000 product specifications and a presence in over 70 countries [2] - Wolai Intelligent Technology Co., Ltd. specializes in smart manufacturing solutions for emerging industries, particularly in the automotive and semiconductor sectors [2] - Gaokai Technology is engaged in precision fluid control, with products used in semiconductor and consumer electronics industries [3] - Deep Blue Ocean Technology Co., Ltd. develops underwater robotics and solutions for various marine applications, holding 15 core technologies in the field [3] - Tongxin Medical Technology Co., Ltd. is an innovative medical device company focused on advanced heart failure treatments, with its first product approved in China and others in clinical trials [4] Group 2: Product Development and Market Position - New Tong Pharmaceutical has developed a first-class innovative drug, with one product already on the market and others in various clinical trial stages [1] - Renben has maintained the top position in domestic bearing production and sales for 12 consecutive years, nearing the capabilities of the top eight global competitors [2] - Wolai is recognized as a national key "little giant" enterprise, providing comprehensive smart manufacturing solutions [2] - Gaokai's product range includes flow control and precision dispensing systems, catering to the needs of intelligent manufacturing [3] - Deep Blue has established itself as a pioneer in the underwater robotics sector, with a complete product line and significant R&D investment [3] - Tongxin's CH-VAD system is the first fully magnetic levitation left ventricular assist device approved in China, with further innovations in the pipeline [4]

Core Viewpoint - New Tong Pharmaceutical has been accepted for IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board, focusing on drug development for major liver diseases such as hepatitis B and liver cancer, with a commitment to innovative drugs that meet clinical needs [1][2]. Group 1: IPO Process - This marks New Tong Pharmaceutical's second attempt at an IPO, having previously completed the entire listing process but ultimately failing to enter the issuance stage before the registration approval expired [2]. - The company submitted its IPO application in December 2021, received approval in April 2023, but could not proceed to issuance before the approval's expiration on April 25, 2024 [2]. Group 2: Product Pipeline and Revenue Dependence - Currently, New Tong Pharmaceutical has one approved innovative drug, Mesylate Prefofovir Tablets, which is expected to be commercially dependent in the short term [3]. - The company anticipates that Mesylate Prefofovir Tablets will be included in the national medical insurance directory by 2025 and will start sales at the insurance price in 2026 [3]. - The company faces risks related to potential price reductions of its products after market entry and the possibility of being removed from the medical insurance directory, which could significantly impact market share and revenue [3]. Group 3: Sales and Distribution Risks - New Tong Pharmaceutical employs an exclusive agency distribution model for Mesylate Prefofovir Tablets, leading to high customer concentration and reliance on a single distributor, KGI Securities [4]. - Revenue from KGI Securities and its subsidiaries accounted for 94.09% and 98.83% of total revenue in 2024 and the first half of 2025, respectively [4]. Group 4: Financial Performance - The company has reported negative net profits for several consecutive years, with a cumulative loss of 347 million yuan as of June 2025 [6]. - Revenue figures for recent years show a significant reliance on the single product, with total revenues of 976.70 million yuan in the first half of 2025, compared to 1,197.82 million yuan in 2023 [7]. - The company has a high R&D expense ratio, with R&D expenses exceeding revenue in recent years, indicating a focus on product development despite ongoing losses [7]. Group 5: Intellectual Property Risks - New Tong Pharmaceutical faces risks related to intellectual property, as some patents for its products have expired, potentially exposing them to generic competition [5]. - The company has applied for additional patents to enhance protection but still faces risks associated with the expiration of the five-year monitoring period for innovative drugs [5].